Dr. Herrera Discusses Polatuzumab Vedotin in DLBCL

Alex Herrera, MD
Published: Thursday, Dec 14, 2017



Alex Herrera, MD, assistant professor, Department of Hematology and Hematologic Cell Transplantation, City of Hope, discusses polatuzumab vedotin in diffuse large B-cell lymphoma (DLBCL).

In phase I studies, single-agent polatuzumab vedotin has proved to be safe to use in this patient population. Investigators wanted to build upon this potential by studying this agent in combination trials.

The addition of polatuzumab vedotin to bendamustine and rituximab (Rituxan) was shown to be tolerable in a phase I study. A phase II randomized study was then conducted and with the addition of polatuzumab vedotin to bendamustine and rituxmab, more patients were able to complete the 6-week cycle than those who did not receive polatuzumab vedotin.

Herrera says that these studies suggest this is an active triplet that is worth studying in this population.
 
SELECTED
LANGUAGE


Alex Herrera, MD, assistant professor, Department of Hematology and Hematologic Cell Transplantation, City of Hope, discusses polatuzumab vedotin in diffuse large B-cell lymphoma (DLBCL).

In phase I studies, single-agent polatuzumab vedotin has proved to be safe to use in this patient population. Investigators wanted to build upon this potential by studying this agent in combination trials.

The addition of polatuzumab vedotin to bendamustine and rituximab (Rituxan) was shown to be tolerable in a phase I study. A phase II randomized study was then conducted and with the addition of polatuzumab vedotin to bendamustine and rituxmab, more patients were able to complete the 6-week cycle than those who did not receive polatuzumab vedotin.

Herrera says that these studies suggest this is an active triplet that is worth studying in this population.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x